Valaciclovir
- Generic Name
- Valaciclovir
- Brand Names
- Valtrex
- Drug Type
- Small Molecule
- Chemical Formula
- C13H20N6O4
- CAS Number
- 124832-26-4
- Unique Ingredient Identifier
- MZ1IW7Q79D
- Background
Valaciclovir (valacyclovir), also known as Valtrex, is an antiviral drug that has been used to manage and treat various herpes infections for more than 2 decades. It was initially approved by the FDA in 1995 and marketed by GlaxoSmithKline . Valacyclovir is the L-valine ester of aciclovir. It is a member of the purine (guanine) nucleoside analog drug class ...
- Indication
Valacyclovir is a nucleoside analog DNA polymerase inhibitor indicated for :
Adults
• Cold Sores (Herpes Labialis)
• Genital Herpes
• Treatment of genital herpes lesions in immunocompetent patients (initial or recurrent episode)
• Suppression of genital herpes lesions in immunocompetent or HIV-infected patients
• Reduction of viral transmission
...
- Associated Conditions
- Chickenpox, Genital Herpes, Genital herpes, initial episode, Herpes Labialis, Herpes Zoster, Recurrent Genital Herpes (RGH)
- Associated Therapies
- Suppression of Recurrent Genital Herpes (RGH)
HSV-2 Suppression to Reduce Maternal HIV-1 RNA Levels During Pregnancy and Breastfeeding
- First Posted Date
- 2007-09-17
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 148
- Registration Number
- NCT00530777
- Locations
- 🇰🇪
Mathare North City Clinic, Nairobi, Kenya
Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV
- First Posted Date
- 2007-09-11
- Last Posted Date
- 2018-06-07
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 28
- Registration Number
- NCT00527618
- Locations
- 🇺🇸
University of Washington Virology Research Clinic, Seattle, Washington, United States
Systematic Evaluation of Antiviral Medication in Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2007-08-10
- Last Posted Date
- 2018-06-14
- Lead Sponsor
- Konasale Prasad
- Target Recruit Count
- 31
- Registration Number
- NCT00514449
- Locations
- 🇺🇸
Wayne State University, Detroit, Michigan, United States
🇺🇸Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
- Conditions
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT00492050
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
- First Posted Date
- 2007-06-14
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 695
- Registration Number
- NCT00486200
HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1 Co-infected Persons
- Conditions
- Interventions
- First Posted Date
- 2007-04-24
- Last Posted Date
- 2013-08-22
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 20
- Registration Number
- NCT00465205
- Locations
- 🇵🇪
Asociacion Civil Impacta Salud y Educacion, Lima, Peru
Research Study of Bipolar Mood Symptoms and Cognitive Problems
- First Posted Date
- 2007-01-30
- Last Posted Date
- 2017-04-11
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 60
- Registration Number
- NCT00428298
- Locations
- 🇺🇸
Johns Hopkins University School of Medicine, Dept. of Psychiatry, Baltimore, Maryland, United States
HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1, HSV-2 Co-infected Men.
- Conditions
- Interventions
- First Posted Date
- 2006-09-21
- Last Posted Date
- 2013-08-22
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 20
- Registration Number
- NCT00378976
- Locations
- 🇵🇪
Asociacion Civil Impacta Salud y Educacion, Lima, Peru
Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
- First Posted Date
- 2006-08-09
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 31
- Registration Number
- NCT00362297
- Locations
- 🇺🇸
University of Washington Virology Research Clinic, Seattle, Washington, United States
Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes
- Conditions
- Interventions
- First Posted Date
- 2006-03-24
- Last Posted Date
- 2011-06-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1179
- Registration Number
- NCT00306787
- Locations
- 🇺🇸
Providence Clinical Research, Burbank, California, United States
🇺🇸Women's Medical Research Group, LLC, Clearwater, Florida, United States
🇺🇸UNC Clinical Research., Raleigh, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.